Longitudinal White Matter Damage Evolution in Parkinson's Disease

Pietro Giuseppe Scamarcia1,2, Federica Agosta1,2,3, Edoardo Gioele Spinelli1,2,3

  • 1Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Abstract

Insights

White matter hyperintensities (WMHs) are linked to cognitive decline in Parkinson's disease (PD). Cerebral white matter microstructural damage does not significantly impact PD progression, but WMHs can predict cognitive impairment development.

Area of Science:

  • Neuroimaging
  • Neurology
  • Gerontology

Background:

  • White matter hyperintensities (WMHs) are implicated in cognitive decline during normal aging.
  • The specific role of WMHs and white matter (WM) microstructural integrity in Parkinson's disease (PD) progression remains debated.

Purpose of the Study:

  • To examine the long-term changes in cerebral white matter (WM) structure.
  • To investigate the relationship between WM alterations and clinical progression in PD patients.

Main Methods:

  • 154 PD patients and 60 controls underwent annual MRI scans and clinical/cognitive assessments for up to 4 years.
  • Tract-based spatial statistics analyzed diffusion tensor (DT) MRI metrics in WM and normal-appearing white matter (NAWM).
  • Linear mixed-effects models and regression analyses assessed longitudinal changes and risk factors for disease progression.

Main Results:

  • PD patients exhibited baseline alterations in DT MRI measures compared to controls.
  • WMH volume increased over time and correlated with cognitive impairments (global, executive, language).
  • Baseline WMH volume moderately predicted progression to mild cognitive impairment.

Conclusions:

  • WMHs are associated with cognitive decline in PD patients.
  • Cerebral white matter microstructural damage has minimal impact on clinical PD progression.
  • MRI-assessed WMHs serve as a valuable tool for monitoring cognitive impairment development in PD.

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
820
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.5K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
440
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
736